Atopic Dermatitis Trial moves to Phase 2b
CAGE Bio, Inc., a clinical-stage biotechnology company dedicated to developing innovative therapies for prevalent immuno-dermatological disorders, today announced the initiation of a Phase 2b dose-ranging trial for its lead product, CGB-500. This topical JAK inhibitor ointment, formulated with CAGE Bio's proprietary ionic liquid technology, aims to provide a breakthrough treatment for moderate to severe atopic dermatitis (AD) with low body surface area (BSA) involvement. CGB-500 is designed to deliver medication directly through the skin, offering high efficacy with minimal systemic exposure. Data from the 2024 Phase 2a trial demonstrated results comparable to biologic therapies, significantly outperforming current leading topical treatments while maintaining a notably lower side-effect profile.
Atopic Dermatitis Trial moves to Phase 2b